Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease

Journal of Bone and Mineral Metabolism

Volumn 28, Issue 6, 2010, Pages 706-712

  Polyzos, Stergios A ^a   Anastasilakis, Athanasios D ^b   Litsas, Ioannis ^a   Efstathiadou, Zoe ^a   Kita, Marina ^a   Arsos, Georgios ^c   Moralidis, Efstratios ^c   Papatheodorou, Athanasios ^d   Terpos, Evangelos ^e  

^a Ippokration Hospital Thessaloniki   (Greece)

^b 424 General Army Hospital   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d 251 GENERAL AIR FORCE HOSPITAL   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Hyperparathyroidism; Hypocalcemia; Juvenile Paget's disease; Paget's disease of bone; Zoledronic acid

Indexed keywords

ALFACALCIDOL; ALKALINE PHOSPHATASE; CALCITONIN; CALCIUM; CALCIUM CARBONATE; COLECALCIFEROL; ETIDRONIC ACID; GLUCONATE CALCIUM; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADOLESCENT DISEASE; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE BOWING; BONE MINERAL; BONE PAIN; BONE SCINTISCANNING; BONE TURNOVER; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEARING IMPAIRMENT; HUMAN; HYPERTELORISM; HYPOCALCEMIA; KYPHOSCOLIOSIS; MACROCEPHALY; PAGET BONE DISEASE; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM; TREATMENT DURATION; WALKING DIFFICULTY;

ADULT; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG MONITORING; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPOCALCEMIA; IMIDAZOLES; OSTEITIS DEFORMANS;

EID: 78349312375     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-010-0198-8     Document Type: Article

References (26)

1. MP Whyte SE Obrecht PM Finnegan JL Jones MN Podgornik WH McAlister S Mumm 2002 Osteoprotegerin deficiency and juvenile Paget's disease N Engl J Med 347 175 184 1:CAS:528:DC%2BD38Xlt12jsL0%3D 10.1056/NEJMoa013096 12124406
2. T Cundy M Hegde D Naot B Chong A King R Wallace J Mulley DR Love J Seidel M Fawkner T Banovic KE Callon AB Grey IR Reid CA Middleton-Hardie J Cornish 2002 A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype Hum Mol Genet 11 2119 2127 1:CAS:528:DC%2BD38Xms1Gnu7o%3D 10.1093/hmg/11.18.2119 12189164
3. S Simsek NM Basoski N Bravenboer X Zhang S Mumm MP Whyte JC Netelenbos 2007 Sporadic hyperphosphatasia syndrome featuring periostitis and accelerated skeletal turnover without receptor activator of nuclear factor-kappaB, osteoprotegerin, or sequestosome-1 gene defects J Clin Endocrinol Metab 92 1897 1901 1:CAS:528:DC%2BD2sXlt1Okurw%3D 10.1210/jc.2006-0479 17284635
4. SH Ralston 2008 Juvenile Paget's disease, familial expansile osteolysis and other genetic osteolytic disorders Best Pract Res Clin Rheumatol 22 101 111 1:CAS:528:DC%2BD1cXjtVWgsL0%3D 10.1016/j.berh.2007.11.005 18328984
5. F Singer E Siris E Shane D Dempster R Lindsay M Parisien 1994 Hereditary hyperphosphatasia: 20 year follow-up and response to disodium etidronate J Bone Miner Res 9 733 738 1:STN:280:DyaK2czjtVCjug%3D%3D 10.1002/jbmr.5650090519 8053403
6. T Cundy J Davidson MD Rutland C Stewart AM DePaoli 2005 Recombinant osteoprotegerin for juvenile Paget's disease N Engl J Med 353 918 923 1:CAS:528:DC%2BD2MXpsFChur8%3D 10.1056/NEJMoa050893 16135836
7. FH Doyle NJ Woodhouse AC Glen GF Joplin I MacIntyre 1974 Healing of the bones in juvenile Paget's disease treated by human calcitonin Br J Radiol 47 9 15 1:STN:280:DyaE2c%2FntVCitQ%3D%3D 10.1259/0007-1285-47-553-9 4809438
8. A Spindler A Berman C Mautalen J Ubios AE Santini 1992 Chronic idiopathic hyperphosphatasia. Report of a case treated with pamidronate and a review of the literature J Rheumatol 19 642 645 1:STN:280:DyaK383nslGqsA%3D%3D 1593590
9. C Tau C Mautalen C Casco V Alvarez M Rubinstein 2004 Chronic idiopathic hyperphosphatasia: normalization of bone turnover with cyclical intravenous pamidronate therapy Bone (NY) 35 210 216 1:CAS:528:DC%2BD2cXltVGjs70%3D
10. T Cundy L Wheadon A King 2004 Treatment of idiopathic hyperphosphatasia with intensive bisphosphonate therapy J Bone Miner Res 19 703 711 10.1359/jbmr.040127 15068492
11. E Demir A Bereket B Ozkan M Topcu 2000 Effect of alendronate treatment on the clinical picture and bone turnover markers in chronic idiopathic hyperphosphatasia J Pediatr Endocrinol Metab 13 217 221 1:STN:280: DC%2BD3c7nsVyisA%3D%3D 10711670
12. GH Nancollas R Tang RJ Phipps Z Henneman S Gulde W Wu A Mangood RG Russell FH Ebetino 2006 Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite Bone (NY) 38 617 627 1:CAS:528:DC%2BD28XjvFSjtr4%3D
13. SA Polyzos AD Anastasilakis E Terpos 2009 Paget's disease of bone: emphasis on treatment with zoledronic acid Expert Rev Endocrinol Metabolism 4 424 434
14. IR Reid P Miller K Lyles W Fraser JP Brown Y Saidi P Mesenbrink G Su J Pak K Zelenakas M Luchi P Richardson D Hosking 2005 Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease N Engl J Med 353 898 908 1:CAS:528:DC%2BD2MXpsFCht7g%3D 10.1056/NEJMoa044241 16135834
15. PD Papapetrou 2009 Bisphosphonate-associated adverse events Hormones (Athens) 8 96 110
16. BG Stuckey EM Lim GN Kent LC Ward DH Gutteridge 2001 Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission J Bone Miner Res 16 1719 1723 1:STN:280:DC%2BD3MvpsleltA%3D%3D 10.1359/jbmr.2001.16.9.1719 11547843
17. HE Whitson B Lobaugh KW Lyles 2006 Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone Bone (NY) 39 954 958 1:CAS:528:DC%2BD28XpsVOgsr0%3D
18. A Avramidis SA Polyzos E Moralidis G Arsos Z Efstathiadou K Karakatsanis G Grollios M Kita 2008 Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone J Bone Miner Metab 26 635 641 1:CAS:528:DC%2BD1cXhtlWhtb%2FI 10.1007/s00774-008-0852-6 18979164
19. SA Khan EV McCloskey KS Eyres K Nakatsuka P Sirtori J Orgee G Coombes JA Kanis 1996 Comparison of three intravenous regimens of clodronate in Paget disease of bone J Bone Miner Res 11 178 182 1:CAS:528:DyaK28XhsF2ksLY%3D 10.1002/jbmr.5650110206 8822341
20. JP Devogelaer P Bergmann JJ Body Y Boutsen S Goemaere JM Kaufman JY Reginster S Rozenberg S Boonen 2008 Management of patients with Paget's disease: a consensus document of the Belgian Bone Club Osteoporos Int 19 1109 1117 10.1007/s00198-008-0629-8 18504638
21. DB Kimmel 2007 Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates J Dent Res 86 1022 1033 1:CAS:528:DC%2BD2sXhtleku7rE 10.1177/154405910708601102 17959891
22. RP Heaney MS Dowell CA Hale A Bendich 2003 Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D J Am Coll Nutr 22 142 146 1:CAS:528:DC%2BD3sXjtlelsLw%3D 12672710
23. GO Stewart DH Gutteridge RI Price L Ward RW Retallack RL Prince BG Stuckey GN Kent CI Bhagat SS Dhaliwal 1999 Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium Bone (NY) 24 139 144 1:CAS:528:DyaK1MXhtVejt7o%3D
24. SA Polyzos AD Anastasilakis E Terpos 2009 Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid Support Care Cancer 17 1329 1330 10.1007/s00520-009-0704-5 19641941
25. S Shankar DJ Hosking 2006 Biochemical assessment of Paget's disease of bone J Bone Miner Res 21 suppl 2 22 27 10.1359/jbmr.06s204
26. SA Polyzos AD Anastasilakis Z Efstathiadou M Kita I Litsas A Avramidis G Arsos E Moralidis S Gerou V Pavlidou A Papatheodorou E Terpos 2009 The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin and RANKL in patients with Paget's disease of bone Horm Metab Res 41 846 850 1:CAS:528:DC%2BC3cXitFSh 10.1055/s-0029-1233491 19670154